Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by loss of memory and cognitive impairment via dysfunction of the cholinergic nervous system. In cholinergic dysfunction, it is well known that impaired cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) signaling are major pathological markers and are some of the strategies for the development of AD therapy. Therefore, this study is aimed at evaluating whether a mixture comprising Ginkgo biloba L. leaf (GL) and Hericium erinaceus (Bull.) Pers. (HE) fruit extract (GH mixture) alleviated cognitive impairment induced in a scopolamine-induced model. It was discovered that GH reduced neuronal apoptosis and promoted neuronal survival by activating BDNF signaling in an in vitro assay. In addition, the GH (p.o. 240 mg/kg) oral administration group significantly restored the cognitive deficits of the scopolamine-induced mouse group (i.p. 1.2 mg/kg) in the behavior tests such as Y-maze and novel object recognition task (NORT) tests. This mixture also considerably enhanced cholinergic system function in the mouse brain. Furthermore, GH markedly upregulated the expressed levels of extracellular signal-regulated kinase (ERK), CREB, and BDNF protein levels. These results demonstrated that GH strongly exerted a neuroprotective effect on the scopolamine-induced mouse model, suggesting that an optimized mixture of GL and HE could be used as a good material for developing functional foods to aid in the prevention of neurodegenerative diseases, including AD.

Highlights

  • Alzheimer’s disease (AD), which involves continuous memory and cognitive dysfunction, is an age-related neurodegenerative disease [1]

  • (pCREB), anti-extracellular signal-regulated kinase (ERK), anti-pERK, anti-protein kinase B (AKT), anti-pAKT, anti-glycogen synthase kinase 3 beta (GSK3β), anti-pGSK3β, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Cell Signaling Technology (Beverly, MA, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), 2′,7′-dichlorofluorescein diacetate (DCFH-DA), scopolamine, and donepezil hydrochloride were obtained from Sigma-Aldrich

  • Further tests were performed using 5 mM scopolamine to investigate the neuroprotective effects of GH on scopolamine-induced cytotoxicity

Read more

Summary

Introduction

Alzheimer’s disease (AD), which involves continuous memory and cognitive dysfunction, is an age-related neurodegenerative disease [1]. It is clear that dysfunction of cholinergic neurons is mainly involved in AD pathogenesis [5]. As acetylcholinesterase inhibitors (e.g., tacrine, rivatigmine, galantamine, and donepezil), have been approved for the treatment of AD, but they only help in keeping symptoms from worsening [6]. They have short half-lives and side effects such as hepatotoxicity and nausea [7]. It is needed to find alternative drugs to treat AD which show strong effects without any toxicity

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.